Mr. Ed Field, Chief Operating Officer at Aldagen, explains the principles behind ALDEFLUOR™-based detection of ALDH bright cells and discusses evidence demonstrating ALDH’s potential as a biomarker for cancer stem cell characterization and tumor prognosis.